Cagrilintides main issues are nausea/fullness during ramp-up
Understanding general peptide response timelines contextualizes expectations across different applications
Single GLP-1 agonism (the semaglutide model) drives appetite suppression and glucose control but plateaus in how much weight it can shift
So Ian and I hopped on a plane and went to Japan back in September and sat down with Mari, and she was gracious enough to break down all of her research, answer Ian's questions
This schedule, documented across SURPASS clinical trials, starts at the lowest therapeutic dose and increases by 2.5 mg every four weeks
For now, these peptides represent a frontier in regenerative medicine, offering hope for conditions like CKD, stroke, and neurodegenerative diseases